Holger Albrecht

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.

Journal: Journal of neurology

Published: August 16, 2021

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients.

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients.

Journal: Frontiers in neurology

Published: December 02, 2020

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab.

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab.

Journal: Multiple sclerosis and related disorders

Published: July 29, 2019

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: July 27, 2018

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: December 24, 2017

New aspects of symptomatic MS treatment: Part 5 - fatigue

New aspects of symptomatic MS treatment: Part 5 - fatigue

Journal: Der Nervenarzt

Published: October 29, 2017

New aspects of symptomatic MS treatment: Part 4-sexual dysfunction and eye movement disorders

New aspects of symptomatic MS treatment: Part 4-sexual dysfunction and eye movement disorders

Journal: Der Nervenarzt

Published: October 29, 2017

New aspects of symptomatic MS treatment: Part 6 - cognitive dysfunction and rehabilitation

New aspects of symptomatic MS treatment: Part 6 - cognitive dysfunction and rehabilitation

Journal: Der Nervenarzt

Published: October 29, 2017

What is new in symptomatic MS treatment: Part 3-bladder dysfunction

What is new in symptomatic MS treatment: Part 3-bladder dysfunction

Journal: Der Nervenarzt

Published: October 29, 2017

What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity

What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity

Journal: Der Nervenarzt

Published: October 25, 2017

What is new in symptomatic MS treatment: Part 1-introduction and methodical approach, ataxia and tremor

What is new in symptomatic MS treatment: Part 1-introduction and methodical approach, ataxia and tremor

Journal: Der Nervenarzt

Published: October 25, 2017

A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis.

A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis.

Journal: European journal of neurology

Published: June 11, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026